PALO ALTO — Revance Therapeutics, Inc., a biotech company developing next-generation forms of Botox, has tapped a team from Cooley to smooth the path toward a projected $86 million initial public offering. Menlo Park–based attorneys from Davis Polk & Wardwell are advising underwriters.
Revance, which is headquartered in Newark, Calif., and was founded in 1999, develops new treatments using botulinum toxin for aesthetic and therapeutic purposes. The company expects to report Phase 3 clinical results for its lead product candidate, a topical gel that improves the appearance of crow’s feet wrinkles, this year. Other products are meant to address issues ranging from migraines to excessive sweating.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
